TABLE 2.
Susceptibility of Candida krusei to voriconazole by clinical service
| Clinical service (total no. of Candida isolates) | No. of C. krusei isolates | % C. krusei isolatesa | % of C. krusei isolates in the following category:
|
||
|---|---|---|---|---|---|
| S | SDD | R | |||
| Hematology-oncology (8,262) | 514 | 6.2 | 76.7 | 13.4 | 9.9 |
| Medical (32,872) | 752 | 2.3 | 82.7 | 8.4 | 8.9 |
| Surgical (8,673) | 218 | 2.5 | 82.6 | 10.1 | 7.3 |
| Intensive care unit (18,215) | 445 | 2.4 | 81.8 | 11.0 | 7.2 |
| Dermatology (2,450) | 25 | 1.0 | 68.0 | 24.0 | 8.0 |
| ObGyn (17,013) | 220 | 1.3 | 77.3 | 14.5 | 8.2 |
| Urology (1,270) | 26 | 2.0 | 73.1 | 15.4 | 11.5 |
| Outpatient (11,438) | 149 | 1.3 | 81.2 | 7.4 | 11.4 |
| Other, NOS (37,294) | 1,099 | 2.9 | 88.5 | 5.9 | 5.6 |
a
C. krusei isolates as a percentage of all Candida isolates from the indicated clinical service.